8-K: Mineralys Therapeutics Completes Enrollment in Phase 2 Trial of Lorundrostat for Hypertension in CKD Patients

Mineralys Therapeutics announces the completion of enrollment in its Explore-CKD Phase 2 trial evaluating lorundrostat for hypertension in chronic kidney disease patients.

Summary

• Mineralys Therapeutics has completed enrollment in its Explore-CKD Phase 2 trial.
• The trial is evaluating the efficacy and safety of lorundrostat for treating hypertension in subjects with chronic kidney disease (CKD) and albuminuria.
• Patients in the trial are already receiving stable treatment with an angiotensin-converting enzyme inhibitor (ACEi) or an angiotensin receptor blocker (ARB) and an SGLT2 inhibitor.
• Topline data from the Explore-CKD trial is anticipated in Q2 2025.
• The Explore-CKD trial is a randomized, double-blind, placebo-controlled, two-period, two-sequence (2x2) crossover trial.
• The primary efficacy endpoint is the change from baseline in systolic blood pressure at week four in the active versus placebo treatment period.
• An exploratory endpoint will evaluate the change from baseline in urine albumin-to-creatinine ratio at week four in the active versus placebo treatment period.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive due to the completion of enrollment in a Phase 2 trial, which is a positive step in the drug development process. However, the forward-looking statements include standard risk disclosures, preventing a higher score.

Positives

• Enrollment completion keeps the trial on track for topline data in Q2 2025.
• The trial expands the spectrum of high-risk patients with poorly controlled hypertension who may benefit from lorundrostat.
• Lorundrostat has shown clinically meaningful blood pressure reduction in previous trials.

Risks

• The company's future performance depends entirely on the success of lorundrostat.
• There are potential delays in the commencement, enrollment, and completion of clinical trials and nonclinical studies.
• The FDA may have later developments that are inconsistent with feedback from the completed end of Phase 2 meeting.
• The company is dependent on third parties in connection with manufacturing, research, and clinical and nonclinical testing.
• Unexpected adverse side effects or inadequate efficacy of lorundrostat may limit its development, regulatory approval, and/or commercialization.
• Unfavorable results from clinical trials and nonclinical studies could occur.
• Results of prior clinical trials and studies of lorundrostat are not necessarily predictive of future results.
• The company's ability to maintain undisrupted business operations could be affected by any pandemic or future public health concerns.
• Regulatory developments in the United States and foreign countries could impact the company.
• The company relies on its exclusive license with Mitsubishi Tanabe Pharma to provide it with intellectual property rights to develop and commercialize lorundrostat.

Future Outlook

The company anticipates announcing topline data from the Explore-CKD trial in Q2 2025 and continues to develop lorundrostat for various cardiorenal conditions.

Management Comments

• 'We are pleased to have completed enrollment in Explore-CKD and be on track to share topline data in the second quarter of 2025,' stated David Rodman, MD, Chief Medical Officer of Mineralys Therapeutics.
• Rodman also noted that Explore-CKD expands the spectrum of high-risk patients with poorly controlled hypertension who may benefit from this novel treatment modality.

Industry Context

The announcement highlights the ongoing efforts to address hypertension in CKD patients, a significant unmet medical need given the high prevalence of CKD and the challenges in achieving blood pressure control with existing medications. The trial's focus on patients already receiving standard treatments (ACEi/ARB and SGLT2 inhibitors) suggests a potential for lorundrostat to provide additive clinical benefits.

Comparison to Industry Standards

• Several companies are developing treatments for hypertension and CKD, including AstraZeneca with Farxiga (dapagliflozin) and Bayer with finerenone, both targeting different pathways.
• Mineralys' lorundrostat, as an aldosterone synthase inhibitor, represents a distinct approach compared to SGLT2 inhibitors and mineralocorticoid receptor antagonists (MRAs).
• The 70% reduction in plasma aldosterone concentration demonstrated by lorundrostat in hypertensive subjects is a notable result compared to other aldosterone-modulating therapies.

Stakeholder Impact

• Positive results from the trial could benefit patients with hypertension and CKD by providing a new treatment option.
• Successful development and commercialization of lorundrostat could increase shareholder value.
• The company's employees are involved in the clinical trial and drug development process.

Next Steps

• The company will analyze the data from the Explore-CKD Phase 2 trial.
• Mineralys Therapeutics anticipates announcing topline data from the Explore-CKD trial in Q2 2025.

Key Dates

Keywords

lorundrostat, hypertension, chronic kidney disease, CKD, Mineralys Therapeutics, clinical trial, Explore-CKD, albuminuria, aldosterone synthase inhibitor